Lipoprotein-associated phospholipase A <sub>2</sub> (Lp-PLA <sub>2</sub> ) as a therapeutic target to prevent retinal vasopermeability during diabetes
Paul Canning(University of Ulster), Alan W. Stitt(Queen's University Belfast), Philip J. Luthert(University College London), Bridget-Ann Kenny(University College Hospital), Patric Turowski(Institute of Ophthalmology), David C. Gale(GlaxoSmithKline (United States)), Natalie Hudson(Trinity College Dublin), Peter Adamson(University College London), Francisco J. López(GlaxoSmithKline (United States)), Josephine V. Glenn(Queen's University Belfast), Martín Brandt(SINTEF), Vivien E. Prise(Queen's University Belfast), Mosharraf H. Sarker(Liverpool John Moores University)
Cited by 69
Related Papers
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line
|The FASEB Journal|2005|1.3k
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
|JCI Insight|2017|1k
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
|Proceedings of the National Academy of Sciences|2012|488